Amid nationwide injectable Naloxone shortage, Pa. entities rely on Narcan supply
Naloxone, an injectable, intramuscular drug approved by the Food and Drug Administration for the rapid reversal of opioid overdoses, has been in scant supply since Pfizer, the drug’s maker, ran into manufacturing issues in 2020, causing the price of the Naloxone to soar even as demand for the drug increased during pandemic-fueled shutdowns, The Guardian reported earlier this month.
With increase in polysubstance use, state agency will ‘expand’ focus from opioid epidemic
The new approach, announced Monday by Department of Drug and Alcohol Programs Secretary Jen Smith, will “expand” the agency's focus to address “the increase of polysubstance and stimulant use across the commonwealth.”
Gov. Wolf asks lawmakers to make an early return to Harrisburg, extend opioid declaration
Gov. Tom Wolf asks Pennsylvania lawmakers to extend the opioid disaster declaration by Aug. 26.
With a rise in overdose deaths, how is Pa. combating the opioid epidemic?
Preliminary data from the state Department of Health show a 14 percent increase in overdose deaths in 2020, compared to 4,458 deaths the year before.